Company Overview - Tian Da Pharmaceutical Co., Ltd. focuses on the development of traditional Chinese medicine, innovative drugs, and healthcare services, aiming to become a competitive player in the pharmaceutical and healthcare sectors [4] - The company is building a comprehensive traditional Chinese medicine industry chain, establishing quality control standards for Chinese medicinal materials, and creating a new type of Chinese medicine clinic called "Tian Da Clinic" [4] - Tian Da Pharmaceutical utilizes internet technology, big data, and artificial intelligence to integrate online and offline services, providing comprehensive healthcare services [4] Financial Performance - As of December 31, 2024, Tian Da Pharmaceutical reported total revenue of 306 million yuan, a year-on-year decrease of 37.99% [2] - The company recorded a net loss attributable to shareholders of 56.83 million yuan, a significant decline of 154.07% year-on-year [2] - The gross profit margin stood at 46.08%, with a debt-to-asset ratio of 33.9% [2] Market Position and Valuation - Currently, there are no institutional investment ratings for Tian Da Pharmaceutical [3] - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 5.44 times, with a median of 4.53 times [3] - Tian Da Pharmaceutical has a P/E ratio of -5.26 times, ranking 125th in the industry [3] - Comparatively, other companies in the sector have P/E ratios ranging from 0.72 times to 4.28 times [3] Recent Stock Performance - As of May 9, the Hang Seng Index increased by 0.4%, closing at 22,867.74 points [1] - Tian Da Pharmaceutical's stock price was 0.162 HKD per share, reflecting an increase of 8.0% with a trading volume of 2,000 shares and a turnover of 326 HKD [1] - Over the past month, the stock has experienced a cumulative decline of 10.71%, and a year-to-date decline of 11.24%, underperforming the Hang Seng Index's increase of 13.54% [2]
天大药业（00455.HK）5月9日收盘上涨8.0%，成交326港元